• DAN DUBÉ
    Dan Dubé is remembered as the vibrant, committed and empathetic champion of the ACC patient community that, more than anyone, he helped build.
  • ACCRF SCIENTIFIC ADVISORY BOARD
    Our Scientific Advisory Board has been fundamental to all the foundation’s activities, laying the groundwork for the remarkable research progress of the past several years.
  • ACC PATIENT COMMUNITY
    The ACC patient community is a diverse, active and caring group of individuals that, despite a cancer diagnosis, continues to lead fulfilling lives.
  • Featured Champion: Dan Dubé
  • ACCRF Scientific Advisory Board
  • ACC Patient Community

Hope is a Powerful Ally.
And Research is the Angel of Hope.

Adenoid cystic carcinoma (ACC) is a rare cancer of secretory glands, typically originating in the head and neck region.

The Adenoid Cystic Carcinoma Research Foundation (ACCRF) supports research into adenoid cystic carcinoma that will accelerate the development of improved therapies and a cure for the disease. Read More…

  • Just Diagnosed? Just Diagnosed?

    Consider these steps
    ACC Physicians List
    Tumor Donations
    ACCOI

  • News & Updates
  • ACCRF Spotlight Watch Our Video

    Learn about ACCRF in this video about the foundation’s activities. Watch the video

  • Quick Facts About ACC
    • ACC is diagnosed in about 1,200 new cases each year and afflicts about 10,000 patients in the United States.
    • ACC’s progression is typically gradual and sometimes relentless. The disease has a tendency to grow along nerves and metastasize to the lungs.
    • ACC is an equal-opportunity disease that might strike anyone. It is not inherited and is not associated with smoking, drinking, infection or ethnicity. Women comprise about 60% of ACC cases.
    • ACC often afflicts young and middle-aged patients. The median age at diagnosis for ACC patients is a decade younger than for all cancer patients.
    • No chemotherapies or targeted drugs have been approved for ACC, though some may be effective in some patients. Research is needed to find effective therapies for ACC patients.
    • With the support of the patient community, ACCRF has spurred significant advances in ACC research that bode well for the future.

  • ACCRF Spotlight Video

  • Quick Facts

  • ACC is diagnosed in about 1,200 new cases each year and afflicts about 10,000 patients in the United States.

    ACC’s progression is typically gradual and sometimes relentless. The disease has a tendency to grow along nerves and metastasize to the lungs.

    ACC is an equal-opportunity disease that might strike anyone. It is not inherited and is not associated with smoking, drinking, infection or ethnicity. Women comprise about 60% of ACC cases.

    ACC often afflicts young and middle-aged patients. The median age at diagnosis for ACC patients is a decade younger than for all cancer patients.

    No chemotherapies or targeted drugs have been approved for ACC, though some may be effective in some patients. Research is needed to find effective therapies for ACC patients.

    With the support of the patient community, ACCRF has spurred significant advances in ACC research that bode well for the future.